The global urology devices market was valued at approximately USD 9.17 billion in 2023 and is expected to expand at a CAGR of 6.78% between 2024 and 2030, reaching USD 13.56 billion by 2030. This growth is primarily driven by the increasing prevalence of chronic urological conditions, including cancers and benign prostatic hyperplasia (BPH), the rising number of elderly patients vulnerable to these disorders, ongoing technological innovations in devices, and a growing preference for minimally invasive surgical procedures. These trends are anticipated to sustain demand for urology devices throughout the 2024–2030 period.
DelveInsight’s Urology Devices Market Insights report offers a comprehensive analysis of current and forecasted market trends, company-specific market shares, key market drivers and barriers, challenges, and notable companies operating in the urology devices sector.
Request for a sample report @ https://www.delveinsight.com/report-store/urology-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:
-
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).
-
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.
-
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).
-
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.
-
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.
-
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER™ program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.
-
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.
-
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.
Key Takeaways from the Urology Devices Market Report
-
The Urology Devices market is expected to experience steady growth at a moderate CAGR between 2025 and 2032.
-
According to DelveInsight, North America is projected to maintain its position as the leading region in the global Urology Devices market throughout the forecast period.
-
Key players in the Urology Devices sector include Boston Scientific Corporation, Baxter, B. Braun Melsungen AG, Medtronic, Laborie, Potent Medical, Advin Health Care, KARL STORZ SE & Co. KG, Fresenius Medical Care AG & Co. KGaA, Coloplast Corporation, Intuitive Surgical, Nipro, Olympus Corporation, Asahi Kasei Medical, Nikkiso Co., Ltd., Well Lead Medical Co., Ltd, Applied Medical Resources Corporation, DirexGroup, Richard Wolf GmbH, Cardinal Health, among others.
Notable recent developments:
-
In February 2023, Boston Scientific Corporation received US FDA 510(k) clearance for its LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System, the first device to enable real-time monitoring of intrarenal pressure during ureteroscopy procedures.
-
In May 2022, Teleflex Incorporated obtained approval from China’s NMPA for its UroLift® System, expanding its presence in the Chinese market.
To read more about the latest highlights related to the Urology Devices market, get a snapshot of the key highlights entailed in the Global Urology Devices Market Report
Urology Devices Overview
The urology devices market is witnessing strong expansion, driven by multiple factors. These include the increasing prevalence of chronic urological conditions such as prostate cancer and benign prostatic hyperplasia (BPH), a rising elderly population more prone to these disorders, and ongoing technological innovations in medical devices. In addition, the growing preference for minimally invasive procedures is boosting the demand for advanced urology instruments and systems. Together, these trends are expected to substantially accelerate the market growth for urology devices between 2024 and 2030.
Urology Devices Market Insights
North America is projected to lead the urology devices market in 2023 and maintain its dominance throughout the forecast period from 2024 to 2030. This leadership is driven by the increasing prevalence of kidney stones and prostate cancer, which are fueling the demand for effective management solutions. Market growth is further supported by technological advancements, regulatory approvals, the strong presence of leading companies, ongoing investments in healthcare infrastructure, and continuous innovations in product development.
The American Urological Association (2024) reports that nearly 1 in 11 people in the U.S. will experience kidney stones in their lifetime, with incidence rates showing an upward trend.
According to Globocan (2024), the U.S. recorded 230,125 prostate cancer cases in 2022, while Canada reported 25,560 cases. Projections indicate that by 2050, prostate cancer cases in North America will rise to 346,000.
The increasing occurrence of kidney stones and prostate cancer is driving demand for urology devices, as the need for effective interventions to manage urinary obstructions grows, making this a rapidly expanding market.
To know more about why North America is leading the market growth in the Urology Devices market, get a snapshot of the Urology Devices Market Outlook
Urology Devices Market Dynamics
According to the Global Cancer Observatory (2024), in 2022, Europe reported 473,011 prostate cancer cases, Asia had 386,424, Latin America and the Caribbean (LAC) accounted for 225,985, and Africa recorded 103,050 cases.
For rectal cancer, Asia reported 417,357 cases, Europe had 181,701, LAC accounted for 43,036, and Africa recorded 27,672 cases.
The National Institutes of Health (2024) indicates that the global prevalence of benign prostatic hyperplasia (BPH) ranges from 50–60% in individuals in their 60s, increasing to 80–90% in those over 70.
Additionally, the World Health Organization (2021) projects that the population aged 60 and above will rise from 12% in 2015 to 22% by 2050, reaching 2.1 billion worldwide, with one in six people globally expected to be 60 or older by 2030.
The increasing incidence of prostate cancer, BPH, and rectal cancer, alongside the growth of the aging population, is driving strong demand for urology devices. These conditions frequently lead to urinary complications, boosting the need for advanced treatment solutions. Furthermore, innovations in medical technology and a growing focus on improving patient outcomes are accelerating market growth, as healthcare systems prioritize effective management of urinary tract obstructions.
Collectively, these factors are expected to propel the urology devices market throughout the forecast period from 2024 to 2030.
Urology Devices Market Drivers:
The urology devices market is witnessing significant growth, fueled by the increasing prevalence of chronic conditions like cancers and benign prostatic hyperplasia (BPH), a growing elderly population at risk, continuous technological advancements in device development, and the rising adoption of minimally invasive procedures. These trends are expected to drive strong demand for urology devices over the forecast period from 2024 to 2030.
Get a sneak peek at the Urology Devices market dynamics @ https://www.delveinsight.com/sample-request/urology-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Coverage: Global
Study Period: 2022 to 2032
Key Urology Devices Companies: Boston Scientific Corporation, Baxter, B. Braun Melsungen AG, Medtronic, Laborie, Potent Medical, Advin Health Care, KARL STORZ SE & Co. KG, Fresenius Medical Care AG & Co. KGaA, Coloplast Corporation, Intuitive Surgical, Nipro, Olympus Corporation, Asahi Kasei Medical, Nikkiso Co., Ltd., Well Lead Medical Co., Ltd, Applied Medical Resources Corporation, DirexGroup, Richard Wolf GmbH, Cardinal Health, and others.
Which MedTech key players in the Urology Devices market are set to emerge as the trendsetter, explore @ Urology Devices Companies
Table of Contents
1. Urology Devices Market Report Introduction
2. Urology Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Urology Devices Market Key Factors Analysis
6. Urology Devices Market Porter’s Five Forces Analysis
7. Urology Devices Market Layout
8. Urology Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
